Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma
Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial testing the regimen as an adjuvant therapy for patients whose melanoma has been surgically removed. While Opdualag is still projected to reach blockbuster status, it could face competition from a Regeneron Pharmaceuticals drug. The post Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma appeared first on MedCity News.
Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial testing the regimen as an adjuvant therapy for patients whose melanoma has been surgically removed. While Opdualag is still projected to reach blockbuster status, it could face competition from a Regeneron Pharmaceuticals drug.
The post Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma appeared first on MedCity News.
